{
    "clinical_study": {
        "@rank": "121214", 
        "brief_summary": {
            "textblock": "To evaluate the safety and tolerance of concurrent administration of standard-dose\n      didanosine (ddI) with low-dose ribavirin in HIV-positive patients. To determine the\n      pharmacokinetic interactions of concurrent administration of ddI and ribavirin and correlate\n      pharmacokinetic parameters with toxicity. To investigate antiviral activity of the combined\n      regimen.\n\n      Combination ddI/ribavirin therapy, if safe and effective, offers an alternative combination\n      antiretroviral regimen for patients unable to tolerate regimens containing zidovudine (AZT)."
        }, 
        "brief_title": "A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals", 
        "completion_date": {
            "#text": "February 1995", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "HIV Seropositivity"
            ]
        }, 
        "detailed_description": {
            "textblock": "Combination ddI/ribavirin therapy, if safe and effective, offers an alternative combination\n      antiretroviral regimen for patients unable to tolerate regimens containing zidovudine (AZT).\n\n      Patients receive ddI alone for 4 weeks, followed by 8 weeks of combination ddI/ribavirin.\n      Patients who complete the first 12 weeks without major toxicity may receive an additional 12\n      weeks of combination therapy on an optional basis. Patients are followed for 60 days after\n      the last treatment visit."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Stable maintenance or prophylaxis therapy for opportunistic infection, if such\n             therapy was administered for at least 30 days prior to study entry.\n\n          -  Isoniazid for chemoprophylaxis against Mycobacterium tuberculosis.\n\n          -  Fluconazole for mucosal candidiasis or cryptococcosis.\n\n          -  Acyclovir (up to 1.0 g/day).\n\n          -  Dapsone.\n\n          -  Ketoconazole.\n\n          -  Quinolones.\n\n          -  Tetracycline.\n\n          -  Vitamins and herbal therapies.\n\n          -  Antibiotics as clinically indicated.\n\n          -  Systemic corticosteroids for < 21 days for acute problems.\n\n          -  Regularly prescribed medications.\n\n        Patients must have:\n\n          -  HIV positivity by ELISA confirmed by Western blot.\n\n          -  CD4 count < 500 cells/mm3 within 30 days prior to study entry.\n\n          -  No active opportunistic infections requiring treatment (patients on stable\n             maintenance and prophylaxis therapy for opportunistic infections for at least 30 days\n             are permitted).\n\n        NOTE:\n\n          -  Enrollment of women is encouraged.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Prior stable maintenance or prophylaxis therapy for opportunistic infection, if\n             administered for at least 30 days prior to study entry.\n\n        Exclusion Criteria\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Concurrent rifampin or rifabutin.\n\n          -  Other anti-HIV drugs and investigational agents.\n\n          -  Biological response modifiers.\n\n          -  Ganciclovir or foscarnet.\n\n          -  Systemic cytotoxic chemotherapy.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Concurrent radiation therapy other than limited localized therapy to the skin.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of peripheral neuropathy.\n\n          -  History of pancreatitis or active liver disease.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Prior ddI.\n\n          -  Ribavirin within 60 days prior to study entry.\n\n          -  AZT or ddC within 2 weeks prior to study entry.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Transfusion within 2 weeks prior to study entry.\n\n        Active alcohol abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "15", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000772", 
            "org_study_id": "ACTG 231", 
            "secondary_id": "11208"
        }, 
        "intervention": [
            {
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Didanosine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Didanosine", 
                "Ribavirin"
            ]
        }, 
        "keyword": [
            "Ribavirin", 
            "Didanosine", 
            "Drug Therapy, Combination", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex"
        ], 
        "lastchanged_date": "March 30, 2012", 
        "link": [
            {
                "description": "Click here for more information about Didanosine", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=16"
            }, 
            {
                "description": "Click here for more information about Ribavirin", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=28"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess - East Campus A0102 CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55455"
                    }, 
                    "name": "University of Minnesota, ACTU"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals", 
        "overall_official": [
            {
                "last_name": "Japour AJ", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Lertora JJ", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Crumpacker C", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "citation": "Japour AJ, et al. A Phase I study of the safety, tolerance, & pharmacokinetics of combination didanosine/ribavirin for HIV disease (ACTG 231). Natl Conf Hum Retroviruses Relat Infect (2nd). 1995 Jan 29-Feb 2:103"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000772"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Bristol-Myers Squibb", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "ICN Pharmaceuticals", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2012"
    }, 
    "geocoordinates": {
        "Beth Israel Deaconess - East Campus A0102 CRS": "42.358 -71.06", 
        "University of Minnesota, ACTU": "44.98 -93.264"
    }
}